Quick Answer
4D Molecular Therapeutics, Inc. reported Net Income Loss of -$140.11 million for the year ending 2025.
- 4D Molecular Therapeutics, Inc. showed an increase of +12.9% in Net Income Loss from 2024 to 2025.
- This data is from 4D Molecular Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$13.16 million | Q2 2020: -$15.15 million | Q3 2020: -$7.83 million | Q1 2021: -$16.41 million | Q2 2021: -$7.59 million | Q3 2021: -$22.24 million | Q1 2022: -$26.34 million | Q2 2022: -$28.09 million | Q3 2022: -$25.69 million | Q1 2023: -$28.68 million | Q2 2023: -$29.62 million | Q3 2023: -$10.26 million | Q1 2024: -$32.40 million | Q2 2024: -$34.95 million | Q3 2024: -$43.84 million | Q1 2025: -$47.97 million | Q2 2025: -$54.66 million | Q3 2025: -$56.88 million.
- Over the full 7 years of available data (2019 to 2025), 4D Molecular Therapeutics, Inc.'s Net Income Loss has declined by 184.2%.
- Historical annual values: Fiscal year 2025: -$140.11 million | Fiscal year 2024: -$160.87 million | Fiscal year 2023: -$100.84 million | Fiscal year 2022: -$107.49 million | Fiscal year 2021: -$71.32 million | Fiscal year 2020: -$56.69 million | Fiscal year 2019: -$49.31 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: